Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

OP032: Outcome of pregnancies in female IBD patients treated with vedolizumabECCO '18 Vienna
Year: 2018
Authors:

A. Moens1,2*, K. van Hoeve2,3, E. Humblet4, J.-F. Rahier5, P. Bossuyt6, S. Dewit7, D. Franchimont8, E. Macken9, J. Nijs10, A. Posen11, A. Van Hootegem12, W. Van Moerkercke13, S. Vermeire1,2, M. Ferrante1,2

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, 3University Hospitals Leuven, Department of Paediatric gastroenterology, Leuven, Belgium, 4Ziekenhuis Oost-Limburg-Campus Sint-Jan, Department of Gastroenterology and Hepatology, Genk, Belgium, 5CHU UCL Namur, Université catholique de Louvain, Yvoir, Belgium, 6Imeldaziekenhuis, Department of Gastroenterology and Hepatology, Bonheiden, Belgium, 7Mariaziekenhuis Noord-Limburg, Department of Gastroenterology and Hepatology, Overpelt, Belgium, 8Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, 9University Hospital Antwerp, Department of Gastroenterology and Hepatology, Antwerp, Belgium, 10Sint-Trudo Ziekenhuis, Department of Gastroenterology and Hepatology, Sint-Truiden, Belgium, 11AZ Vesalius, Department of Gastroenterology and Hepatology, Tongeren, Belgium, 12AZ Klina, Department of Gastroenterology and Hepatology, Brasschaat, Belgium, 13AZ Groeninge, Department of Gastroenterology and Hepatology, Kortrijk, Belgium

OP033: The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programmeECCO '18 Vienna
Year: 2018
Authors:

B.E. Sands1, P.R. Taub2, B.G. Feagan3*, A. Armuzzi4, G.S. Friedman5, M. Moscariello5, N. Lawendy5, R.D. Pedersen5, G. Chan5, C.I. Nduaka5, D. Quirk5, L. Salese5, C. Su5

1Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, NY, USA, 2UC San Diego School of Medicine, Division of Cardiovascular Medicine, La Jolla, CA, USA, 3Western University, Robarts Clinical Trials, London, ON, Canada, 4Presidio Columbus Fondazione Policlinico Gemelli Università Cattolica, IBD Unit, Rome, Italy, 5Pfizer Inc., Collegeville, PA, USA

OP034: The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registryECCO '18 Vienna
Year: 2018
Authors:

M. Calafat1,2*, M. Mañosa3,4, F. Cañete3, J. Panés4,5, V. García Sánchez4,6, M. Calvo7, F. Rodríguez-Moranta8, C. Taxonera9, P. Nos4,10, A. López Sanromán11, M.D. Martín Arranz12, M. Mínguez13, J.P. Gisbert4,14, S. García-López15, R. de Francisco16, F. Gomollón4,17, X. Calvet4,18, E. Garcia-Planella19, M. Rivero20, J. Martínez-Cadilla21, F. Argüelles22, L. Arias García23, M. Cimavilla24, Y. Zabana4,25, L. Márquez26, A. Gutiérrez4,27, G. Alcaín28, P. Martínez Montiel29, J. Lázaro30, D. Busquets31, M.F. García Sepulcre32, C. Verdejo33, F. Bermejo34, M. Mora35, D. Monfort36, P. Romero37, B. Velayos38, C. Rodríguez39, A. Rodríguez40, O. Merino41, A. Rodríguez-Pescador42, L. Bujanda4,43, Y. Ber44, M. Vela45, O. Roncero46, J.M. Huguet47, O. García-Bosch48, M. Barreiro-de-Acosta49, R.E. Madrigal50, L. Ramos51, M. Van Domselaar52, P. Almela53, J. Llaó54, A.J. Lucendo4,55, C. Muñoz Vilafranca56, À. Abad57, M. Charro58, J. Legido59, J. Riera1, S. Khorrami60, E. Sesé61, A.M. Trapero62, E. Domènech3,4

1Hospital Son Llàtzer, Palma, Spain, 2Universitat Autònoma de Barcelona, Barcelona, Spain, 3Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 4CIBERehd Instituto de Salud Carlos III, Madrid, Spain, 5Hospital Clínic, Barcelona, Spain, 6Hospital Reina Sofia, Córdoba, Spain, 7Hospital Puerta de Hierro, Majadahonda, Spain, 8Hospital Bellvitge, L’Hospitalet de Llobregat, Spain, 9Hospital Clínico San Carlos, Madrid, Spain, 10Hospital La Fe, Valencia, Spain, 11Hospital Ramón y Cajal, Madrid, Spain, 12Hospital La Paz, Madrid, Spain, 13Hospital Clínico de Valencia, Valencia, Spain, 14Hospital La Princesa, Madrid, Spain, 15Hospital Universitario Miguel Servet, Zaragoza, Spain, 16Hospital Universitario Central de Asturias, Oviedo, Spain, 17Hospital Clínico Lozano Blesa, Zaragoza, Spain, 18Hospital Parc Taulí, Sabadell, Spain, 19Hospital Santa Creu i Sant Pau, Barcelona, Spain, 20Hospital Universitario Marqués de Valdecilla, Santander, Spain, 21Complexo Hospital Universitario de Vigo, Vigo, Spain, 22Hospital Virgen de la Macarena, Sevilla, Spain, 23Hospital Universitario Burgos, Burgos, Spain, 24Hospital Río Hortega, Valladolid, Spain, 25Hospital Mutua de Terrassa, Terrassa, Spain, 26Hospital del mar, Barcelona, Spain, 27Hospital General Universitario de Alicante, Alicante, Spain, 28Hospital Clínico de Málaga, Málaga, Spain, 29Hospital 12 de octubre, Madrid, Spain, 30Hospital Universitario Fundación Alcorcón, Alcorcón, Spain, 31Hospital Dr Josep Trueta, Girona, Spain, 32Hospital General Universitario de Elche, Elche, Spain, 33Hospital General de Ciudad Real, Ciudad Real, Spain, 34Hospital Universitario Fuenlabrada, Fuenlabrada, Spain, 35Hospital Manises, Manises, Spain, 36Consorci sanitari de Terrassa, Terrassa, Spain, 37Hospital Santa Lucía, Cartagena, Spain, 38Hospital Clínico Universitario Valladolid, Valladolid, Spain, 39CH de Navarra, Pamplona, Spain, 40Hospital Universitario de Salamanca, Salamanca, Spain, 41Hospital de Cruces, Barakaldo, Spain, 42Hospital Galdakao, Galdakao, Spain, 43Instituto Biodonostia UPV/EHU, (Donostia, Spain, 44Hospital San Jorge, Huesca, Spain, 45Hospital Nuestra Sra Candelaria, Sta Cruz Tenerife, Spain, 46Hospital Mancha Centro, Alcazar de San Juan, Spain, 47Hospital General Universitario Valencia, Valencia, Spain, 48Hospital Moisès Broggi, St Joan Despí, Spain, 49CH Santiago, Santiago de Compostela, Spain, 50CH de Palencia, Palencia, Spain, 51Hospital Universitario de Canarias, La Laguna, Spain, 52Hospital Torrejón, Torrejón, Spain, 53HG de Castelló, Castelló, Spain, 54Hospital Sant Joan de Déu-Althaia, Manresa, Spain, 55Hospital General de Tomelloso, Tomelloso, Spain, 56Hospital Basurto, Bilbao, Spain, 57Hospital Viladecans, Viladecans, Spain, 58Hospital Royo Vilanova, Zaragoza, Spain, 59Hospital General, Segovia, Spain, 60Hospital Son Espases, Palma, Spain, 61Hospital Arnau de Vilanova, Lleida, Spain, 62Complejo Hospitalario de Jaén, Jaén, Spain

OP035: NUDT15 variants contribute to thiopurine-induced myelosuppression in European populationsECCO '18 Vienna
Year: 2018
Authors:

G. Walker1,2*, J. Harrison3, M. Voskuil4, G. Heap1,2, N. Heerasing1,2, P. Hendy1,2, J. Koskela5,6, M. Daly5,6, H. Sokol7, D. McGovern8, R. Weersma4, C. Bewshea1, M. Weedon3, J. Goodhand1,2, N. Kennedy1,2, T. Ahmad1,2, IBD Pharmacogenetics Study Group

1University of Exeter, IBD Pharmacogenetics, Exeter, UK, 2Royal Devon and Exeter NHS Foundation Trust, Department of Gastroenterology, Exeter, UK, 3University of Exeter, Exeter Medical School Bioinformatics Team, Exeter, UK, 4University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands, 5The Broad Institute of MIT and Harvard, Cambridge, USA, 6Massachusetts General Hospital, Analytical and Translational Genetics Unit, Boston, USA, 7Hôpital Saint-Antoine, Service de Gastroentérologie et Nutrition, Paris, France, 8Cedars-Sinai Medical Center, Inflammatory Bowel Disease Center, Division of Gastroenterology, Los Angeles, USA

OP036: Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with inflammatory bowel disease: a nationwide cohort studyECCO '18 Vienna
Year: 2018
Authors:

M. de Jong1*, S. van Tilburg1,2, L. Nissen2, W. Kievit1, I. Nagtegaal3, F. Hoentjen1, L. Derikx1,2

1Radboud University Nijmegen Medical Centre, Gastroenterology and Hepatology, Nijmegen, The Netherlands, 2Jeroen Bosch Hospital, Gastroenterology and Hepatology, S Hertogenbosch, The Netherlands, 3Radboud University Nijmegen Medical Centre, Pathology, Nijmegen, The Netherlands

OP037: Risk of cancer in inflammatory bowel disease patients is associated with age and recent use of immunomodulators, while biologics and aminosalicylates are protective factors: a cross-sectional and follow-up analysis of the Swiss IBD cohort studyECCO '18 Vienna
Year: 2018
Authors:

T. Greuther1*, S. Scharl1, C. Barthel1, J.-B. Rossel2, L. Biedermann1, B. Misselwitz1, S. Vavricka1, G. Rogler1, M. Scharl1, on behalf of the Swiss IBD Cohort Study Group

1University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, 2University Hospital Lausanne - CHUV, Institute of Social and Preventive Medicine, Lausanne, Switzerland

OP038: Hobit- and Blimp1-driven tissue resident memory T cells critically control chronic intestinal inflammationECCO '18 Vienna
Year: 2018
Authors:

S. Zundler1*, E. Becker1, M. Spocinska1, L. Parga-Vidal2, R. Stark2, R. Atreya1, T. Rath1, M. Leppkes1, C. Neufert1, I. Atreya1, K. van Gisbergen2, M.F. Neurath1

1University of Erlangen-Nuremberg, Department of Medicine I, Erlangen, Germany, 2Academic Medical Center, Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands

P001: Establishment of in vitro human model for ulcerative colitis by using human colon organoid cultureECCO '18 Vienna
Year: 2018
Authors:

S. Hibiya1*, K. Tsuchiya1, S. Watanabe1, R. Nishimura1, T. Shirasaki1, S. Oshima1, R. Okamoto1, T. Nakamura2, M. Watanabe3

1Tokyo Medical and Dental University, Center for Stem Cell and Regenerative Medicine, Tokyo, Japan, 2Tokyo Medical and Dental University, Advanced Therapeutics for Gastrointestinal Diseases, Tokyo, Japan, 3Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan

P002: Epithelial to mesenchymal transition is a hallmark of fibrostenosing Crohn’s disease and is associated with down regulation of the miR-200 familyECCO '18 Vienna
Year: 2018
Authors:

S.J. Mehta1*, A. Lewis1, A. Nijhuis1, R. Jeffery1, R. Feakins1,2, A. Silver1, J.O. Lindsay1,3

1Blizard Institute, London, UK, 2Barts Health NHS Trust, Histopathology, London, UK, 3Barts Health NHS Trust, Gastroenterology, London, UK

P003: Identification of a novel therapeutic agent for treating Crohn’s disease guided by systems medicineECCO '18 Vienna
Year: 2018
Authors:

M. Burkitt1,2*, K. Lloyd1, S. Papoutsopopoulou1,3, E. Smith3, A. Kel4, P. Stegmaier4, W. Müller3, C. Probert1,2, The SysmedIBD Consortium

1The University of Liverpool, Cellular and Molecular Physiology, Liverpool, UK, 2Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, UK, 3University of Manchester, Department of Immunology, Manchester, UK, 4GeneXplain, Wolfenbüttel, Germany

P004: Altered colonic mucosal oxylipins and endocannabinoids levels in treatment-naive and deep remission ulcerative colitis patientsECCO '18 Vienna
Year: 2018
Authors:

J. Diab1*, S. Gouveia2, T. Hansen1, E. Jensen1, T. Moritz2, R. Goll3, J. Florholmen3, G. Forsdahl1

1Natural Products and Medicinal Chemistry Research Group, Department of pharmacy, University of Tromsø The Arctic University of Norway, Tromsø, Norway, 2Swedish Metabolomics Center, Swedish University of Agricultural Sciences, Umeå, Sweden, 3Research Group of Gastroenterology and Nutrition, Department of Clinical Medicine, University of Tromsø The Arctic University of Norway, Tromsø, Norway

P005: A multi-marker serum test to assess the presence of ulcerations in infliximab treated patients with Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

M. de Bruyn1,2*, T. Bessissow3, V. Kondragunta4, A. Jain4, I. Arijs5, G. Van Assche1,6, M. Ferrante1,6, G. Opdenakker2, S. Vermeire1,6

1Translational Research center for GastroIntestinal Disorders (TARGID), Chronic Diseases, Metabolism and Ageing (CHROMETA), Leuven, Belgium, 2Rega Institute for Medical Research, Microbiology and Immunology, Leuven, Belgium, 3McGill University, Gastroenterology, Montreal, Canada, 4Prometheus Laboratories, Research and Development, San Diego, USA, 5Hasselt University/Jessa Hospital, Faculty of Medicine and Life Sciences, Hasselt, Belgium, 6University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium

P006: Anatomical brain changes in active Crohn’s disease patientsECCO '18 Vienna
Year: 2018
Authors:

G. Thapaliya1*, S. Eldeghaidy2, S.J. Radford1, M. Lingaya1, Y. Falcone1, S. Francis2, G. Moran1

1The University of Nottingham, National Institute for Health Research (NIHR) Biomedical Research Centre in Gastrointestinal and Liver disease at Nottingham University Hospitals NHS Trust, Queens Medical Centre Campus, Nottingham, UK, 2The University of Nottingham, Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, Nottingham, UK

P007: Activation of pH-sensing receptor OGR1 (GPR68) induces ER stress and autophagy in an intestinal epithelial cell modelECCO '18 Vienna
Year: 2018
Authors:

C. Maeyashiki*, H. Melhem, K. Baebler, S. Lang, M. Scharl, G. Rogler, C. de Valliere

University Hospital Zurich, Zurich, Switzerland

P008: Differences in macrophage infiltration and Wnt ligands expression between stricturing and penetrating behaviour in Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

P. Salvador1, D.C. Macias-Ceja2, J. Cosin-Roger2*, R. Alos3, J. Hinojosa del Val4, F. Navarro-Vicente4, J. Manyé5, S. Calatayud6, D. Barrachina6, D. Ortiz-Masia6,7

1Universidad de Valencia, Pharmacology, Valencia, Spain, 2FISABIO Hospital Peset, Pharmacology, Valencia, Spain, 3Hospital de Sagunto, Surgical Department, Sagunto, Spain, 4Hospital de Manises, Gastroenterology Department, Manises, Spain, 5Institut d’Investigació Germans Trias i Pujol, Badalona, Spain, 6Universidad de Valencia-CIBERehd, Pharmacology, Valencia, Spain, 7Universidad de Valencia, Medicine, Valencia, Spain

P009: Autophagy-related host factors are implicated in the incapability of macrophages from Crohn’s disease patients to mediate adherent-invasive E. coli clearanceECCO '18 Vienna
Year: 2018
Authors:

C. Douadi1*, A. Buisson1,2, L. Ouchchane3, M. Goutte1,2, J.-P. Hugot4, A. Dubois1, R. Minet-Quinard5, D. Bouvier5, G. Bommelaer2, E. Vazeille1,2, N. Barnich1

1M2iSH Laboratory UMR 1071 Inserm / UCA, Clermont-Ferrand, France, 2Gastroenterology Department, University Hospital Estaing, Clermont-Ferrand, France, 3Biostatistics unit, Auvergne University, Clermont-Ferrand, France, 4UMR843, Inserm, Assistance Publique Hôpitaux de Paris et Université, Paris Diderot, Clermont-Ferrand, France, 5Biochemistry laboratory, University Hospital Estaing, Clermont-Ferrand, France

P010: Serum proteomic profiling in Crohn’s disease patients undergoing ileocolonic resection reveals discriminative inflammatory markers for endoscopic recurrenceECCO '18 Vienna
Year: 2018
Authors:

K. Machiels1*, M. de Bruyn1, S. Verstockt1, B. Verstockt1, G. Van Assche1, A. Wolthuis2, A. d'Hoore2, M. Ferrante1, S. Vermeire1

1University Hospitals Leuven, KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 2University Hospitals Leuven, Abdominal surgery, Leuven, Belgium

P011: Host–microbial crosstalk in the pathogenesis of colon cancer in Primary sclerosing cholangitisECCO '18 Vienna
Year: 2018
Authors:

M. Neyazi1*, Oxford IBD cohort study investigators1, S.P.L. Travis1, C. Arancibia1, F. Powrie2, A. Geremia1

1John Radcliffe Hospital, University of Oxford, Translational Gastroenterology Unit, Oxford, UK, 2Kennedy Institute of Rheumatology, Department of NDORMS, Oxford, UK

P012: Identification of ectopic olfactory receptor gene in ulcerative colitis patients and functional analysis of OR51E2 using ex vivo culture of colonic organoid in both human and miceECCO '18 Vienna
Year: 2018
Authors:

B.J. Lee*, M.K. Joo, H.J. Kim, J.-J. Park, J.S. Kim, Y.T. Bak, J.S. Koo, Y.T. Jeen

Korea University, Internal medicine, Seoul, South Korea

P013: Immunophenotyping of peripheral whole blood from 743 IBD patients identifies patterns of association between immune cell populations and T-cell subsets with disease occurrence, severity and medication useECCO '18 Vienna
Year: 2018
Authors:

R. Kosoy1,2, S. Kim-Schulze3, A. Rahman1,4, L. Peters1,2, A. El-ad1, J. Perrigoue5, A. Castillo6, J. Rogers6, A. Atreja6, A. Hurley1,2, M. Merad3, J.F. Colombel6, M. Dubinsky7, J.R. Friedman5, C. Brodmerkel5, S. Plevy5, E. Schadt1, B. Sands6, A. Kasarskis1,2, C. Argmann1,2, M. Suarez-Farinas1,2,8*

1Icahn School of Medicine at Mount Sinai, Genetics and Genomics Sciences, New York, USA, 2Icahn Institute for Genomics and Multiscale Biology, New York, USA, 3Icahn School of Medicine at Mount Sinai, Hematology and Medical Oncology, New York, USA, 4Icahn School of Medicine at Mount Sinai, Human Immune Monitoring Center, New York, USA, 5Janssen R&D, Spring House, PA, USA, 6Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, USA, 7Icahn School of Medicine at Mount Sinai, Pediatric GI and Hepatology, New York, USA, 8Icahn School of Medicine at Mount Sinai, Population Health Science and Policy, New York, USA